bluebird bio Inc to Present New Data at the European Hematology Association (EHA) Congress Conference Call Transcript
Good day, ladies and gentlemen, and welcome to the EHA Data Review and ZYNTEGLO Approval Webcast Conference Call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to introduce your host for today's conference, Ms. Jenn Snyder, Head of Corporate Communications. You may begin.
Thank you, operator, and good morning, everyone. Thank you for joining this morning's call. We issued 2 press releases today on data from our programs being presented this year at EHA, which can be found on the Investor Relations section of our website.
Before we begin, let me review our safe harbor statement. Today's discussion contains statements that are forward-looking under the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations and assumptions that are subject to risks and uncertainties and involve a number of risk factors that could cause actual results to differ materially from projected results. In
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |